Lung Cancer - Other

JANS Article

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

April 19, 2023 | Mark FergusonBronze Contributor

This study used lung cancer screening trial low dose CT scans to develop a model (Sybil) that predicts the likelihood of development of a lung cancer within the next year. The model was then tested...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

April 19, 2023 | Mark FergusonBronze Contributor

This study used lung cancer screening trial low dose CT scans to develop a model (Sybil) that predicts the likelihood of development of a lung cancer within the next year....

JANS Article

Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery Guidelines for the Prevention of Cancer-Associated Venous Thromboembolism in Thoracic Surgery

March 23, 2023 | Cameron LindSilver Contributor

Thoracic oncology patients are a high-risk group for venous thromboembolism (VTE). The ESTS and AATS panel reviewed the evidence using the GRADE approach and made twenty-four recommendations for VTE prophylaxis,...

JANS Article

FDA Approves Drug Which Makes Lung Cancer Glow

January 6, 2023 | Cameron LindSilver Contributor

The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light....

JANS Article

In Global News: 3D Heart Simulations to Treat Arrhythmias, Early Discharge Safe for TAVR Patients, and Favorable Outcomes Related to 4L Lymph Node Dissection

September 14, 2018 | Emily RobinsonBronze Contributor

Patient Care and General Interest 3D personalized simulations of patient hearts reportedly allow physicians to better locate and treat arrhythmias. A six-year-old girl became the first patient to receive congenital...

JANS Article

PACIFIC: Time for a Surgical IIIA Uprising

August 20, 2018 | Mark FergusonBronze Contributor

This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.

...
JANS Article

In Global News: World Lung Cancer Day, Percutaneous Tricuspid Repairs, and a Notebook for Cancer Treatment Management

July 27, 2018 | Claire Vernon

Patient Care and General Interest A woman developed a combination planner, record-keeping notebook, and journal to help her husband through his treatment for esophageal cancer, and other patients now use...

JANS Article

Sarcopenia in Resected NSCLC: Effect on Postoperative Outcomes

July 6, 2018 | Mark FergusonBronze Contributor

This retrospective study of 328 patients undergoing resection for non-small cell lung cancer demonstrated that sarcopenia determined by psoas muscle mass on computed tomography was associated with increased postoperative complications...

JANS Article

Nivolumab Plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden

May 31, 2018 | Mark FergusonBronze Contributor

This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was...

JANS Article

Pembrolizumab Plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

May 30, 2018 | Mark FergusonBronze Contributor

The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.

...
JANS Article

Higher Lung Cancer Incidence in Young Women Than Young Men in the United States

May 23, 2018 | Mark FergusonBronze Contributor

The age-specific incidence of non-small cell lung cancer has reversed in individuals born since the 1960s, with women now having a higher incidence than men. This trend is not explained...

JANS Article

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

May 23, 2018 | Mark FergusonBronze Contributor

This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21...

LOAD MORE
ADVERTISE ON CTSNET